EGFR Non-Small Cell Lung Cancer Pipeline

DelveInsight’s, “EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) - Pipeline Insight, 2026” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

EGFR Non-Small Cell Lung Cancer Understanding

EGFR Non-Small Cell Lung Cancer Overview

EGFR-positive Non-Small Cell Lung Cancer (EGFR+ NSCLC) is a subtype of non-small cell lung cancer characterized by activating mutations in the epidermal growth factor receptor (EGFR) gene. NSCLC accounts for approximately 85% of all lung cancers, and EGFR mutations are particularly common in adenocarcinoma histology, non-smokers, women, and Asian populations. These mutations lead to uncontrolled tumor growth and are important because they can be specifically targeted with EGFR tyrosine kinase inhibitors (TKIs), improving survival and disease control.
The exact cause of EGFR-mutated NSCLC is not completely understood, but several genetic and environmental risk factors contribute to its development. Tobacco smoke remains the leading overall risk factor for lung cancer, however, EGFR mutations are more frequently observed in individuals with minimal or no smoking history. Additional contributing factors include exposure to air pollution, radon gas, asbestos, secondhand smoke, and inherited genetic susceptibility. Somatic mutations in the EGFR gene arise during a person’s lifetime and drive abnormal cellular growth and resistance to apoptosis.
In EGFR+ NSCLC, activating mutations in the EGFR gene result in continuous activation of intracellular signaling pathways such as the RAS-RAF-MEK-ERK and PI3K-AKT-mTOR pathways. These signaling cascades stimulate uncontrolled cell proliferation, angiogenesis, invasion, and inhibition of programmed cell death. Persistent EGFR signaling also promotes tumor metastasis and resistance mechanisms over time. The molecular dependence of these tumors on EGFR signaling explains the effectiveness of EGFR-targeted therapies.

Diagnosis of EGFR+ NSCLC involves imaging studies, histopathological examination, and molecular testing. Initial evaluation typically includes chest X-ray, CT scan, PET scan, and bronchoscopy or biopsy to confirm NSCLC histology. Once NSCLC is identified, tumor tissue or plasma is tested for EGFR mutations using polymerase chain reaction (PCR), next-generation sequencing (NGS), or other molecular diagnostic techniques. Accurate molecular profiling is critical for selecting targeted therapies and determining prognosis.

Treatment of EGFR+ NSCLC primarily involves EGFR tyrosine kinase inhibitors (TKIs), which selectively inhibit abnormal EGFR signaling. Commonly used EGFR TKIs include osimertinib, erlotinib, gefitinib, afatinib, and dacomitinib. Osimertinib is currently preferred for many patients because of its effectiveness against central nervous system metastases and resistance mutations such as T790M. Depending on disease stage, surgery, radiation therapy, chemotherapy, immunotherapy, or combination approaches may also be used. Continuous monitoring is necessary because tumors can develop acquired resistance to EGFR-targeted treatment over time.

"EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) pipeline landscape is provided which includes the disease overview and EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) treatment guidelines. The assessment part of the report embraces, in depth EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

EGFR Non-Small Cell Lung Cancer Pipeline Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) R&D. The therapies under development are focused on novel approaches to treat/improve EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC). 

EGFR Non-Small Cell Lung Cancer Emerging Drugs Analysis

This segment of the EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Emerging Drugs

AK112: Summit Therapeutics

AK112, also known as ivonescimab is a novel, potential first-in-class bispecific antibody being developed by Summit Therapeutics for EGFR-mutated non-small cell lung cancer (EGFR+ NSCLC). The drug’s mechanism of action combines dual blockade of programmed death-1 (PD-1) and vascular endothelial growth factor (VEGF) within a single molecule, thereby simultaneously enhancing anti-tumor immune responses and inhibiting tumor angiogenesis. In EGFR-positive NSCLC, AK112/ivonescimab is specifically being evaluated in patients with locally advanced or metastatic EGFR-mutated non-squamous NSCLC who progressed after third-generation EGFR tyrosine kinase inhibitor therapy. The drug received U.S. FDA Fast Track designation for this indication in combination with platinum-based chemotherapy for adult patients with EGFR-mutated locally advanced or metastatic NSCLC following EGFR-TKI progression. The FDA has accepted for filing a biologics license application (BLA) for ivonescimab (AK112) in combination with chemotherapy for the treatment of patients with EGFR-mutated, locally advanced or metastatic nonsquamous non–small cell lung cancer (NSCLC).1 The application specifically targets patients whose disease has progressed following treatment with a third-generation tyrosine kinase inhibitor (TKI), such as osimertinib (Tagrisso). The FDA has assigned a Prescription Drug User Fee Act goal action date of November 14, 2026.

APL-101: Apollomics Inc.

APL-101 oral capsules, are a novel, potent, selective, orally bioavailable small-molecule c-Met tyrosine kinase inhibitor being developed for non-small cell lung cancer (NSCLC) and other solid tumors with MET dysregulation. In EGFR-positive NSCLC, the mechanism of action of APL-101 involves selective inhibition of the c-Met receptor kinase pathway, which is frequently activated as a resistance mechanism following EGFR tyrosine kinase inhibitor therapy, by blocking aberrant c-Met signaling, the drug aims to suppress tumor cell proliferation, invasion, metastasis, and treatment resistance. Apollomics is also evaluating APL-101 in combination with osimertinib for EGFR-mutated NSCLC. For this indication and broader NSCLC with MET genomic tumor aberrations, the drug received U.S. FDA Orphan Drug Designation. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC). 

ANS02: Avistone Biotechnology Co., Ltd.

ANS02 is a novel fourth-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) being developed by Avistone Biotechnology Co., Ltd. for EGFR-positive non-small cell lung cancer (EGFR+ NSCLC) and other solid tumors. The drug is designed to selectively inhibit mutant EGFR signaling, including resistant EGFR mutations that emerge after earlier-generation EGFR-TKI therapy, thereby suppressing tumor cell proliferation and survival in EGFR-driven cancers. The indication focus includes EGFR-mutated NSCLC, particularly treatment-resistant disease. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC). 

NXP900: Nuvectis Pharma, Inc.

NXP900 is an investigational oral small-molecule for EGFR-positive non-small cell lung cancer (EGFR+ NSCLC) and other solid tumors with SRC/YES1 pathway activation. The drug’s mechanism of action involves selective inhibition of SRC family kinases (SFKs), including SRC and YES1, through a unique Type 1.5 inhibition mechanism that blocks both the catalytic and scaffolding functions of SRC kinase, thereby producing comprehensive shutdown of downstream oncogenic signaling pathways involved in tumor proliferation, metastasis, and resistance to EGFR inhibitors. In EGFR-mutated NSCLC, NXP900 is specifically being evaluated in combination with osimertinib to overcome acquired resistance following prior EGFR-TKI therapy. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC). 

Further product details are provided in the report……..

EGFR Non-Small Cell Lung Cancer Drug Therapeutic Assessment

This segment of the report provides insights about the different EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) drugs segregated based on following parameters that define the scope of the report, such as:

 Major EGFR Non-Small Cell Lung Cancer Players in EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC)

There are approx. 25+ key companies which are developing the therapies EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC). The companies which have their EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) drug candidates in the most advanced stage, i.e. Registration include, Summit Therapeutics, and others.

EGFR Non-Small Cell Lung Cancer Clinical Trial Phases

DelveInsight’s report covers around 30+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

EGFR Non-Small Cell Lung Cancer Drug Route of Administration

EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal 
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

EGFR Non-Small Cell Lung Cancer Product Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

EGFR Non-Small Cell Lung Cancer Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

EGFR Non-Small Cell Lung Cancer Clinical Trial Activities 

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) therapeutic drugs key players involved in developing key drugs. 

EGFR Non-Small Cell Lung Cancer Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) drugs.

EGFR Non-Small Cell Lung Cancer Pipeline Report Insights

•  EGFR Non-Small Cell Lung Cancer Pipeline Analysis
• EGFR Non-Small Cell Lung Cancer Therapeutic Assessment
• EGFR Non-Small Cell Lung Cancer Unmet Needs
• Impact of  EGFR Non-Small Cell Lung Cancer Drugs

EGFR Non-Small Cell Lung Cancer Pipeline Report Assessment

• EGFR Non-Small Cell Lung Cancer Pipeline Product Profiles
• EGFR Non-Small Cell Lung Cancer Therapeutic Assessment
• EGFR Non-Small Cell Lung Cancer Pipeline Assessment
• EGFR Non-Small Cell Lung Cancer Inactive drugs assessment
• EGFR Non-Small Cell Lung Cancer Market Unmet Needs

Key Questions Answered In the EGFR Non-Small Cell Lung Cancer Pipelin Report

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) drugs?
• How many EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC)?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) and their status?
• What are the key designations that have been granted to the emerging drugs?

EGFR Non-Small Cell Lung Cancer Key Players

• Summit Therapeutics
• Apollomics Inc.
• BeBetter Med Inc
• Lantern Pharma Inc.
• Betta Pharmaceuticals Co., Ltd.
• Avistone Biotechnology Co., Ltd.
• BlossomHill Therapeutics
• J Ints Bio
• Nuvectis Pharma, Inc.
• Pierre Fabre Medicament
• Shanghai Best-Link Bioscience, LLC

EGFR Non-Small Cell Lung Cancer Key Products

• AK112
• APL-101
• BEBT-109
• LP-300
• MCLA-129
• ANS02
• BH-30643
• JIN-A02 
• NXP900 
• STX-241 
• STX-721
• BL0020